MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406740 | Name: JNK-IN-8
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JNK-IN-8, also known as JNK Inhibitor XVI, is a selective JNK inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue. Extensive biochemical, cellular, and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggests that the compound will be broadly useful as a pharmacological probe of JNK-dependent signal transduction.

Chemical Structure

JNK-IN-8
JNK-IN-8
CAS#1410880-22-6

Theoretical Analysis

MedKoo Cat#: 406740

Name: JNK-IN-8

CAS#: 1410880-22-6

Chemical Formula: C29H29N7O2

Exact Mass: 507.2383

Molecular Weight: 507.60

Elemental Analysis: C, 68.62; H, 5.76; N, 19.32; O, 6.30

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,150.00 Ready to ship
1g USD 3,250.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
JNK-IN-8; JNK-IN 8; JNK-IN8; JNK Inhibitor XVI; c-Jun N-terminal Kinase Inhibitor XVI.
IUPAC/Chemical Name
(E)-3-(4-(dimethylamino)but-2-enamido)-N-(3-methyl-4-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide
InChi Key
GJFCSAPFHAXMSF-UXBLZVDNSA-N
InChi Code
InChI=1S/C29H29N7O2/c1-20-17-24(11-12-25(20)34-29-31-15-13-26(35-29)22-8-5-14-30-19-22)33-28(38)21-7-4-9-23(18-21)32-27(37)10-6-16-36(2)3/h4-15,17-19H,16H2,1-3H3,(H,32,37)(H,33,38)(H,31,34,35)/b10-6+
SMILES Code
CN(C/C=C/C(NC1=CC=CC(C(NC2=CC=C(C(C)=C2)NC3=NC=CC(C4=CN=CC=C4)=N3)=O)=C1)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
JNK-IN-8 (JNK Inhibitor XVI) is the first irreversible JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 4.7 nM, 18.7 nM and 1 nM, >10-fold selectivity against MNK2, Fms and no inhibition to c-Kit, Met, PDGFRβin A375 cell line.
In vitro activity:
Before assessing the effects of JNK-IN-8 on primary murine peritoneal macrophages, the cytotoxic effect of JNK-IN-8 on cells was assessed using a CCK-8 assay (Fig. 4A). No significant cytotoxic effects of JNK-IN-8 were observed at concentrations of ≤12.50 µM in primary macrophages (Fig. 4A). Based on these data, a maximal concentration of 10 µM was selected to analyze the effects of JNK-IN-8 in primary macrophages. In order to investigate the anti-inflammatory effect of JNK-IN-8, primary macrophages were pretreated with JNK-IN-8 for 1 h and then stimulated with LPS (100 ng/ml) for 6 h. mRNA expression levels and secretion of TNF-α, IL-6 and IL-1β in the LPS group were significantly increased compared with those in the Sham group, but these were decreased in the LPS + JNK-IN-8 group compared with the LPS group (Fig. 4B and C). Subsequently, the role of JNK-IN-8 in oxidative stress was investigated. JNK-IN-8 pretreatment significantly decreased MDA content and inhibited the LPS-induced decrease in SOD activity (Fig. 4D) in primary macrophages. The effects of JNK-IN-8 on the macrophage cell line RAW264.7 were assessed. In the CCK-8 assay, no cytotoxic effects of JNK-IN-8 were observed at concentrations ≤12.50 µM in RAW264.7 cells (Fig. 5A). RAW264.7 cells were cultured and treated with JNK-IN-8 in vitro. The trend was the same as that of primary macrophages. RAW264.7 cells were pretreated with JNK-IN-8 for 1 h and then stimulated with LPS (100 ng/ml) for 6 h. The gene expression levels and secretion of TNF-α, IL-6 and IL-1β were decreased by JNK-IN-8 pretreatment compared with those in the LPS group (Fig. 5B and C). JNK-IN-8 administration significantly decreased the MDA content and inhibited the LPS-induced decrease in SOD activity (Fig. 5D). Reference: Mol Med Rep. 2021 Feb;23(2):150. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33355369/
In vivo activity:
Male rats were treated with JNK-IN-8 after transient middle cerebral artery occlusion, and then the modified improved neurological function score (mNSS), the foot-fault test (FFT), interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) levels were assessed. It was found that JNK-IN-8-treated rats with MCAO exerted an observable melioration in space learning as tested by the improved mNSS, and showed sensorimotor functional recovery as measured by the FFT. JNK-IN-8 also played anti-inflammatory roles as indicated through decreased activation of microglia and decreased IL-6, IL-1β, and TNF-α expression. Furthermore, JNK-IN-8 suppressed the activation of JNK and nuclear factor-κB (NF-κB) signaling as indicated by the decreased level of phosphorylated-JNK and p65. All data demonstrate that JNK-IN-8 inhibits neuroinflammation and improved neurological function by inhibiting JNK/NF-κB and is a promising agent for the prevention of ischemic brain injury. Reference: J Cell Physiol. 2020 Mar;235(3):2792-2799. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31541462/
Solvent mg/mL mM
Solubility
DMSO 100.0 197.01
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 507.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Du J, Wang G, Luo H, Liu N, Xie J. JNK‑IN‑8 treatment alleviates lipopolysaccharide‑induced acute lung injury via suppression of inflammation and oxidative stress regulated by JNK/NF‑κB signaling. Mol Med Rep. 2021 Feb;23(2):150. doi: 10.3892/mmr.2020.11789. Epub 2020 Dec 23. PMID: 33355369; PMCID: PMC7789102.
In vivo protocol:
1. Zheng J, Dai Q, Han K, Hong W, Jia D, Mo Y, Lv Y, Tang H, Fu H, Geng W. JNK-IN-8, a c-Jun N-terminal kinase inhibitor, improves functional recovery through suppressing neuroinflammation in ischemic stroke. J Cell Physiol. 2020 Mar;235(3):2792-2799. doi: 10.1002/jcp.29183. Epub 2019 Sep 20. PMID: 31541462; PMCID: PMC6916328. 2. Du J, Wang G, Luo H, Liu N, Xie J. JNK‑IN‑8 treatment alleviates lipopolysaccharide‑induced acute lung injury via suppression of inflammation and oxidative stress regulated by JNK/NF‑κB signaling. Mol Med Rep. 2021 Feb;23(2):150. doi: 10.3892/mmr.2020.11789. Epub 2020 Dec 23. PMID: 33355369; PMCID: PMC7789102.
1: Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Wang J, Gray NS, Dalby KN, Bartholomeusz C, Ueno NT. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene. 2016 Dec 12. doi: 10.1038/onc.2016.417. [Epub ahead of print] PubMed PMID: 27941886. 2: Li D, Liu N, Zhao L, Tong L, Kawano H, Yan HJ, Li HP. Protective effect of resveratrol against nigrostriatal pathway injury in striatum via JNK pathway. Brain Res. 2017 Jan 1;1654(Pt A):1-8. doi: 10.1016/j.brainres.2016.10.013. PubMed PMID: 27769789. 3: Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, LoGrasso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR, Gray NS. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54. doi: 10.1016/j.chembiol.2011.11.010. PubMed PMID: 22284361; PubMed Central PMCID: PMC3270411. 4: Pathria G, Garg B, Garg K, Wagner C, Wagner SN. Dual c-Jun N-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma. Br J Dermatol. 2016 Dec;175(6):1221-1231. doi: 10.1111/bjd.14713. PubMed PMID: 27145925. 5: Li Q, Song XM, Ji YY, Jiang H, Xu LG. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem Biophys Res Commun. 2013 Nov 1;440(4):701-6. doi: 10.1016/j.bbrc.2013.09.130. PubMed PMID: 24103749.